rs3758524 — LTBR LTBR regulatory variant

LTBR Regulatory Variant — Gating the Alternative NF-κB Pathway

The lymphotoxin beta receptor (LTBR)¹¹ lymphotoxin beta receptor (LTBR)
A member of the TNF receptor superfamily encoded on chromosome 12p13.31; binds lymphotoxin-α1β2 and the LIGHT cytokine is a critical organizer of secondary lymphoid tissue architecture and innate immune tone. rs3758524 is a regulatory intronic variant associated with altered LTBR expression. Carriers of the minor A allele may have reduced LTBR signaling output — a change with consequences for how the immune system organizes lymphoid structures and mounts defenses against intracellular pathogens.

The A allele is rare across all populations, occurring in roughly 1–5% of individuals globally, with higher frequencies observed in East Asian populations (approximately 2–5%) compared to Europeans (~1%) or Africans (~1%). Most people carry the common GG genotype.

The Mechanism

LTBR sits at the hub of a dual NF-κB signaling network. When bound by its ligands, LTBR engages the classical IKKβ/IKKγ complex²² When bound by its ligands, LTBR engages the classical IKKβ/IKKγ complex
This leads to rapid degradation of IκBα and transient activation of RelA:p50 dimers, producing an acute inflammatory response. In parallel, LTBR triggers the alternative (non-canonical) NF-κB pathway³³ alternative (non-canonical) NF-κB pathway
This pathway uses NIK (NF-κB-inducing kinase) and IKKα to process p100 into p52, generating sustained RelB:p52 complexes that drive lymphoid organogenic genes. These two pathways operate independently and are not redundant — together, they shape chemokine gradients, follicular dendritic cell maturation, and stromal cell function in lymph nodes and spleen.

Regulatory variants that reduce LTBR expression dampen both arms of this response⁴⁴ Regulatory variants that reduce LTBR expression dampen both arms of this response
Reduced surface receptor density means less signal transduction per ligand-binding event, blunting both the acute RelA response and the sustained RelB organogenic response. The net effect is subtly impaired lymphoid tissue organization and reduced innate capacity to respond to certain pathogens.

The Evidence

LTBR's role in infection defense is most directly established in mycobacterial models. Blocking LTβR signaling in mice infected with Mycobacterium bovis BCG impaired granuloma formation in the spleen, suppressed macrophage activation, reduced nitric oxide synthase activity, and shifted immune responses from Th1 (IFN-γ) to Th2 (IL-4)⁵⁵ Blocking LTβR signaling in mice infected with Mycobacterium bovis BCG impaired granuloma formation in the spleen, suppressed macrophage activation, reduced nitric oxide synthase activity, and shifted immune responses from Th1 (IFN-γ) to Th2 (IL-4)
A soluble LTβR-IgG1 fusion protein was used to block signaling. Critically, the LTBR and TNF receptor pathways are non-redundant⁶⁶ non-redundant
Blocking both simultaneously caused extensive splenic necrosis — neither compensates for the other.

For the specific rsid, direct human genetic association data is limited. However, the broader LTBR variant literature provides biological grounding. A study of LTBR rs12354 in hepatitis B found that the T allele was significantly enriched in HBV spontaneous resolvers⁷⁷ A study of LTBR rs12354 in hepatitis B found that the T allele was significantly enriched in HBV spontaneous resolvers
GT genotype: 38.4% in resolvers vs 22.2% in chronically infected patients (p = 0.004), suggesting that genetic differences in LTBR function modulate viral infection outcomes. LTBR promoter variants (rs3759334 and rs2364480) were associated with IgA nephropathy in Korean children⁸⁸ LTBR promoter variants (rs3759334 and rs2364480) were associated with IgA nephropathy in Korean children
rs3759334 dominant model p = 0.017; rs2364480 allele p = 0.041, implicating LTBR in immune-complex-mediated inflammatory disease susceptibility.

In the context of juvenile idiopathic arthritis and systemic sclerosis, LTBR pathway activity influences tertiary lymphoid structure (TLS) formation at inflamed joints and fibrotic tissues — a mechanism under active investigation. The evidence base for rs3758524 specifically is emerging, with no large-scale genetic association studies published to date.

Practical Implications

Carriers of the A allele face a modestly altered baseline of LTBR-mediated immune signaling. The main practical concerns are in two areas: susceptibility to certain intracellular pathogens that rely on granuloma-mediated containment, and potentially altered risk of inflammatory conditions where tertiary lymphoid structures shape disease chronicity. Given the rarity of the A allele and the emerging state of the evidence, the actionable focus is on monitoring and early intervention for infections rather than any specific preventive supplement or avoidance.

Interactions

LTBR signaling interacts functionally with the TNF receptor pathway (TNFR1/TNFR2), and these pathways show additive rather than redundant effects in controlling intracellular infections. LTBR-driven alternative NF-κB also intersects with LIGHT/HVEM signaling (TNFRSF14, rs1886730), which shares ligands and downstream targets. Variants in the classical NF-κB arm (RELA, NFKB1) could modulate how much compensation occurs when LTBR signaling is reduced.